| P/E (FY) | — | Sales (TTM) | $0 |
| Earnings (TTM) | -$29.5M | ROE | −66.88% |
| Net Margin | — | ROIC | — |
| Debt / Equity | — | TD / EBITDA | — |
| EPS Growth 3Y | — | Sales Growth 3Y | — |
SELLAS Life Sciences Group is a late-stage clinical biopharmaceutical company developing therapeutics for various cancer indications in the United States. Its lead candidate is galinpepimut-S, a peptide immunotherapy targeting Wilms tumor 1 antigen, alongside SLS009, a selective CDK9 inhibitor. The company has collaborations with Merck & Co. to evaluate GPS combined with pembrolizumab, GenFleet Therapeutics, and Memorial Sloan Kettering Cancer Center.
| Market Cap | $1.88B | Trading Days | 2147 |
| 52W High | 15.88 |
| 52W Low | 1.39 |
| % Off High | −36.46% |
| YTD | 167.64% | 1Y | 466.85% |
| 3Y | 507.83% | 5Y | 14.53% |
| Since incept. (ann.) | −34.77% |
| Ann. Volatility (1Y) | 102.80% | Ann. Volatility (3Y) | 95.41% |
| Sharpe (1Y) | 2.24 | Sharpe (3Y) | 1.14 |
| Max Drawdown (1Y) | −36.24% | Max Drawdown (3Y) | −71.98% |
| Beta (3Y, vs SPY) | 1.54 |
| Ticker | Name | Mkt cap | P/E |
|---|---|---|---|
| OCUL | OCULAR THERAPEUTIX, INC | $1.85B | — |
| TYRA | Tyra Biosciences, Inc. | $1.84B | — |
| AUPH | Aurinia Pharmaceuticals Inc. | $1.92B | 7.2 |
| STOK | Stoke Therapeutics, Inc. | $1.83B | — |
| DMRA | Damora Therapeutics, Inc. | $1.81B | — |
| PGEN | PRECIGEN, INC. | $1.97B | — |
| ANIP | ANI PHARMACEUTICALS INC | $1.98B | 24.4 |
| URGN | UroGen Pharma Ltd. | $1.99B | — |
| BCAX | Bicara Therapeutics Inc. | $1.77B | — |
| RAPP | Rapport Therapeutics, Inc. | $2.01B | — |
| VRDN | Viridian Therapeutics, Inc.\DE | $2.01B |
| — |
| SNDX | Syndax Pharmaceuticals Inc | $1.74B | — |
